AI Article Synopsis
- The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has greatly affected global health and economies, with no fully approved treatments available yet.
- While vaccines are authorized for emergency use and given to high-risk individuals, there are still gaps in controlling the virus.
- Researchers and drug manufacturers are collaborating to fast-track potential therapies by assessing existing drugs and new candidates in clinical trials aimed at tackling COVID-19.
Article Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 has severely impacted global health and economy. There is currently no effective approved treatment for COVID-19; although vaccines have been granted emergency use authorization in several countries, they are currently only administered to high-risk individuals, thereby leaving a gap in virus control measures. The scientific and clinical communities and drug manufacturers have collaborated to speed up the discovery of potential therapies for COVID-19 by taking advantage of currently approved drugs as well as investigatory agents in clinical trials. In this review, we stratified some of these candidates based on their potential targets in the progression of COVID-19 and discuss some of the results of ongoing clinical evaluations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937511 | PMC |
| http://dx.doi.org/10.4110/in.2021.21.e7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Can computer simulation support strategic service planning? Modelling a large integrated mental health system on recovery from COVID-19.
Int J Ment Health Syst
December 2024
Bristol, North Somerset and South Gloucestershire Integrated Care Board, UK National Health Service, Bristol, UK.
Genomic Patterns are Associated with Different Sequelae of Patients with Long-Term COVID-19.
Adv Sci (Weinh)
December 2024
State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory of Pathobiology Ministry of Education, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
In the post-large era, various COVID-19 sequelae are getting more and more attention to health problems. Although the mortality rate of the COVID-19 infection is now declining, it is often accompanied by new clinical sequelae with different symptoms such as fatigue after infection, loss of smell. The degree of age, gender, virus infection seems to be weakly correlated with clinical symptoms.
View Article and Find Full Text PDFCoinfection of severe acute respiratory syndrome coronavirus 2 and polyomavirus in a patient with coronavirus disease 2019 detected by enrichment next-generation sequencing: a case report.
J Med Case Rep
December 2024
Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia.
Background: Severe acute respiratory syndrome coronavirus 2 was found first in Wuhan and declared a pandemic by the World Health Organization. Coinfection with other respiratory viruses may occur, complicating the diagnosis and treatment of coronavirus disease 2019 . Herein, we identified a Karolinska Institute polyomavirus Stockholm 60 present in a nasopharyngeal swab of a patient with severe acute respiratory syndrome coronavirus 2 infection using next-generation sequencing with an enrichment method.
View Article and Find Full Text PDFCOVID-19 infection and later risk of sickness absence by socioeconomic status: a cohort study.
BMC Public Health
December 2024
Finnish Institute of Occupational Health, TYÖTERVEYSLAITOS, PL 18, Helsinki, 00032, Finland.
Background: The COVID-19 pandemic was a significant health risk and resulted in increased sickness absence during the pandemic. This study examines whether a history of COVID-19 infection is associated with a higher risk of subsequent sickness absence.
Methods: In this prospective cohort study, 32,124 public sector employees responded to a survey on COVID-19 infection and lifestyle factors in 2020 and were linked to sickness absence records before (2019) and after (2021-2022) the survey.
Clinical and ultrasound characteristics in patients with sars-cov-2 pneumonia, associated with hospitalization prognosis. e-covid project.
BMC Pulm Med
December 2024
Centre d'Atenció Primària Onze de Setembre. Gerència Territorial de Lleida, Institut Català de La Salut, Passeig 11 de Setembre,10 , 25005, Lleida, Spain.
Background: During the COVID-19 pandemia, the imaging test of choice to diagnose COVID-19 pneumonia as chest computed tomography (CT). However, access was limited in the hospital setting and patients treated in Primary Care (PC) could only access the chest x-ray as an imaging test. Several scientific articles that demonstrated the sensitivity of lung ultrasound, being superior to chest x-ray [Cleverley J et al.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!